Reboxetine for acute treatment of major depression: Systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

BMJ (Online)

Volumn 341, Issue 7777, 2010, Pages 816-

  Eyding, Dirk ^a,b   Lelgemann, Monika ^c   Grouven, Ulrich ^b,d   Härter, Martin ^e,g   Kromp, Mandy ^b   Kaiser, Thomas ^b,g   Kerekes, Michaela F ^b   Gerken, Martin ^f   Wieseler, Beate ^b,g  

^a German Cancer Society   (Germany)

^b INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^c Medical Advisory Service of Social Health Insurance   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF BREMEN   (Germany)

^g Department of Medical Psychology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; IMIPRAMINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SOLVEX; UNCLASSIFIED DRUG;

ADULT; BIBLIOGRAPHIC DATABASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA EXTRACTION; DATA SYNTHESIS; DOUBLE BLIND PROCEDURE; EMBASE; FEMALE; GERMANY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCINFO; PUBLICATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEROTONIN UPTAKE; SINGLE BLIND PROCEDURE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; MORPHOLINES; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 77958142340     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4737     Document Type: Review

References (67)

1. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004;10:23-44. (Pubitemid 38381173)
2. Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev 2003;9:327-42.
3. Pharmacia Limited. Summary of product characteristics: Edronax 4 mg tablets. 2009. www.medicines.org.uk/EMC/medicine/8386/ SPC/Edronax+4mg+Tablets/ #INDICATIONS.
4. Preskorn SH. Reboxetine: a norepinephrine selective reuptake pump inhibitor. J Psychiatr Pract 2004;10:57-63. (Pubitemid 38133755)
5. Schwabe U, Paffrath D. [Drug prescription report] [German]. Springer, 2009.
6. Ferguson JM, Mendels J, Schwart GE. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression. Int Clin Psychopharmacol 2002;17:45-51. (Pubitemid 34169645)
7. Montgomery S, Ferguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 2003;23:45-50. (Pubitemid 36164425)
8. Papakostas GI, Nelson JC, Kasper S, Möller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008;18:122-7. (Pubitemid 350296847)
9. Chuluunkhuu G, Nakahara N, Yanagisawa S, Kamae I. The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. Kobe J Med Sci 2008;54:E147-58. (Pubitemid 352039826)
10. National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults (updated edition). NICE national clinical practice guideline 90. 2010. http:// www.nice.org.uk/ nicemedia/live/12329/45896/45896.pdf.
11. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
12. Institute for Quality and Efficiency in Health Care. [Bupropion, mirtazapine and reboxetine in the treatment of depression: final report; commission no A05-20C] [German]. 2009. www.iqwig.de/ download/A05- 20C-Abschlussbericht-Bupropion-Mirtazapin-und-Reboxetin-bei- Depressionen.pdf.
13. Institute for Quality and Efficiency in Health Care. Bupropion, mirtazapine and reboxetine in the treatment of depression: executive summary of final report; commission no A05-20C. 2009. www.iqwig.de/download/A05- 20C-Executive-Summary-Bupropion-mirtazapine-and-reboxeti ne-in-depression.pdf.
14. Institute for Quality and Efficiency in Health Care. General methods: version 3.0. 2008. www.iqwig.de/download/ IQWiG-General-methods-V-3-0.pdf.
15. Institute for Quality and Efficiency in Health Care. [Bupropion, mirtazapine and reboxetine in the treatment of depression: report plan; commission no A05-20C; version 1.0] [German]. 2008. www. iqwig.de/download/08- 10-07-A05- 20C-Berichtsplan-Version-1-Bupropion-Mirtazapin-und-Reboxe tin-bei-der-Behandlung-der-Depression.pdf.
16. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
17. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach andmeta-regression. StatMed 2002;21:589-624. (Pubitemid 34141379)
18. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006;20:91-6.
19. Ferguson JM,Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:9-14.
20. Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 2003;18:151-6. (Pubitemid 36571059)
21. Institute for Quality and Efficiency in Health Care. [Bupropion, mirtazapine and reboxetine in the treatment of depression: preliminary report; commission no A05-20C] [German]. 2009. www. iqwig.de/download/A05- 20C-Vorbericht-Bupropion-Mirtazapin-und-Reboxetin-bei-Depres sionen.pdf.
22. Institute for Quality and Efficiency in Health Care. Bupropion, mirtazapine and reboxetine in the treatment of depression: executive summary of preliminary report; commission no A05-20C. 2009. http://www.iqwig.de/download/ A05- 20C-Executive-summary-preliminary-report-Bupropion-mirtazapi ne-and-reboxetine-in-the-treatment-of-depression.pdf.
23. Schwartz G, Such P, Schatzberg A. Reboxetine vs venlafaxine in the treatment of severe major depression [abstract]. Eur Neuropsychopharmacol 2002;12:204S.
24. Barbui C, Cipriani A, Brambilla P, Hotopf M. "Wish bias" in antidepressant drug trials? J ClinPsychopharmacol 2004;24:126-30.
25. Bech P, Tanghoj P, Andersen HF, Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) 2002;163:20-5. (Pubitemid 34985308)
26. Ban TA, Gaszner P, Aguglia E, Batista R, Castillo A, Lipcsey A, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998;13:29-39S.
27. Sterling T. Publication decisions and their possible effects on inferences drawn from tests of significances. J Am Stat Assoc 1959;54:30-4.
28. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41.
29. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4:1-115.
30. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-5.
31. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:1-193.
32. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research: a narrative review. Trials 2010;11:37.
33. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
34. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
35. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic reviewof the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 2008;3:e3081.
36. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. (Pubitemid 38669189)
37. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71.
38. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i) ased medicine: selective reporting from studies sponsored by pharmaceutical industry; review of studies in new drug applications. BMJ 2003;326:1171-3.
39. Food and Drug Administration. FDA Amendments Act (FDAAA) of 2007, public law no 110-85 § 801. 2007. http://frwebgate.access. gpo.gov/cgi-bin/getdoc. cgi? dbname=110-cong-public-laws&docid=f:publ085.110.pdf.
40. Regulation (EC) no 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official J Eur Commun 2004;47:L1-33.
41. Regulation (EC) no 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) no 1768/92, directive 2001/20/ EC, directive 2001/83/EC and regulation (EC) no 726/2004. Official J Eur Commun 2006;49:L1-9.
42. Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. Reboxetine, a newnoradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22:393-9. (Pubitemid 34810329)
43. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotoninselective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11:17-23S.
44. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997;7:49-55S.
45. Pharmacia Limited. Multicentre, multinational double-blind study of the activity and tolerability of reboxetine vs fluoxetine and placebo in patients suffering frommajor depressive episodes (phase III): results of patient self-evaluation assessment instrument; addendum to final report no 9550080 of study CTN014-FCE20124. 1995. www.iqwig. de/download/Studie-014.pdf.
46. Pharmacia Limited. Multicentre, multinational double-blind study of the activity and tolerability of reboxetine vs imipramine and placebo in patients suffering frommajor depressive episodes (phase III): final report of study CTN015-FCE20124. 1995. www.iqwig.de/download/ Studienbericht-zu-Studie-015.pdf.
47. Massana J, Möller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80. (Pubitemid 29149865)
48. Pharmacia Limited. Multicentre, multinational double-blind study of the activity and tolerability of reboxetine vs fluoxetine in patients suffering from major depressive episodes (phase III): final report of study CTN016-FCE20124. 1995. www.iqwig.de/download/ Studienbericht-zu-Studie-016.pdf.
49. Pharmacia Limited. Reboxetine (PNU-155950E) vs fluoxetine in a double-blind study for the treatment ofmajor depressive disorders in Taiwan: study report for M/2020/0032. 2001. www.iqwig.de/ download/Studie-032.pdf.
50. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 2006;26:121-7. (Pubitemid 43740334)
51. Pharmacia Limited. Efficacy and tolerability of reboxetine (PNU- 155950E) compared to citalopram in a double-blind study in patients with major depressive disorder: study no Z2020 0043; abbreviated study report; final version. 2003. www.iqwig.de/ download/Studie-043.pdf.
52. Pharmacia & Upjohn. Comparison of placebo and three fixed doses of reboxetine in a population of patients with major depression: a phase II, double-blind, randomized, parallel group, multicenter study of 3 fixed doses of reboxetine or placebo, given orally twice daily to adult patients with major depressive disorder; final report of the trial 95-CRBX-045. 2001. www.iqwig.de/download/ Studienbericht-zu-Studie-045.pdf.
53. Pharmacia & Upjohn. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder: a phase III, randomized, double-blind, placebo- and active-treatmentcontrolled, parallel-group, 8-week study of reboxetine, given orally twice daily to adult patients with major depressive disorder; final report of the study protocol M/2020/0046. 2001. www.iqwig.de/ download/Studie-046.pdf.
54. Pharmacia & Upjohn. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder: a phase III, randomized, double-blind, placebo- and active-treatmentcontrolled, parallel-group, 8-week study of reboxetine, given orally twice daily to adult patients with major depressive disorder: final report of the study protocol M/2020/0047. 2001. www.iqwig.de/ download/Studie-047.pdf.
55. Pharmacia & Upjohn. Reboxetine (PNU-155950E) versus placebo in the treatment of major depressive disorders: final report of the trial protocol number 97-CRBX049. 2001. www.iqwig.de/download/ Studienbericht-zu-Studie-049. pdf.
56. Pharmacia & Upjohn. Reboxetine (PNU-155950E) versus placebo and fluoxetine in a controlled, randomized, double-blind, multicenter study of treatment in major depressive disorders: final report of the study protocol 97-CRBX-050. 2001. www.iqwig.de/ download/Studie-050.pdf.
57. Pharmacia & Upjohn. Reboxetine (PNU-155950E) vs paroxetine in a double-blind, multinational study of treatment in major depressive disorder: final report of the study 97-CRBX-052. 2004. www.iqwig. de/download/Studie-052. pdf.
58. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34. (Pubitemid 30056350)
59. Versiani M. The selective noradrenaline re-uptake inhibitor reboxetine has an early onset of antidepressant action. Int J Psychiatry Clin Pract 2000;4:293-7. (Pubitemid 32057652)
60. Pharmacia Limited. Phase II placebo-controlled clinical study with reboxetine in major depressions: study CTN:20124/ADE 091; clinical study report. 1993. www.iqwig.de/download/ Studienbericht-zu-Studie-091.pdf.
61. Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants: a comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 2006;95:119-23. (Pubitemid 46107028)
62. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: structure and content of clinical study reports E3; current step 4 version. 1995. www.ich.org/LOB/ media/MEDIA479.pdf.
63. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a metaanalysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
64. Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Safety Med 2008:73-81. (Pubitemid 351526054)
65. Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 2007;191:82-3. (Pubitemid 47035186)
66. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005;162:1957-60. (Pubitemid 41428627)
67. Kelly RE Jr, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A, et al. Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med 2006;36:1647-56. (Pubitemid 44575810)